Change in ACPA status during the initial three months in relation to radiographic outcome during 2 years
| Anti-cVim | Anti-CEP-1 | Anti-cFib | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0-/3-months antibody status | −/− (n=178) | +/− (n=21) | +/+ (n=54) | p Value* | −/− (n=153) | +/− (n=14) | +/+ (n=85) | p Value* | −/− (n=179) | +/− (n=12) | +/+ (n=60) | p Value* |
| SHS total score at baseline | 1 (0–6) | 1 (0–4.5) | 2 (0–5) | 0.66 | 1 (0–5) | 2.5 (0–6) | 2 (0–6.5) | 0.73 | 1 (0–5) | 4 (0–7.5) | 3 (0–6) | 0.81 |
| SHS total score at 2 years | 4 (0–12) | 0 (0–10.5) | 7 (3.8–13.3) | 0.012 | 4 (0–10) | 5 (0–13.5) | 9 (3–16) | 0.33 | 4 (0–10) | 9 (4–21) | 9.5 (2–13.8) | 0.72 |
| Change in total score during 2 years | 1 (0–6) | 0 (0–4) | 4 (0–10.3) | 0.015 | 1 (0–5) | 1.5 (0–7) | 4 (0–11.5) | 0.65 | 1 (0–5) | 5 (0–13.3) | 3.5 (0–9) | 0.59 |
Values are median (IQR) van der Heijde modified Sharp score (SHS).
*As calculated by Mann–Whitney U test comparing +/− and +/+.
ACPA, anticitrullinated protein antibody; cVim, citrullinated vimentin peptide; CEP-1, citrullinated α-enolase peptide-1; cFib, citrullinated fibrinogen peptide.